SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine
SPD476-202
Phase 2 small_molecule completed
Quick answer
SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine for Colitis, Ulcerative is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Colitis, Ulcerative
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed